Pfizer Inc. is objecting to the request by several plaintiffs suing over antidepressant Effexor who claim that the pharmaceutical company should produce electronically stored information in its “native” format.
The plaintiffs argue that the production of native files would not be burdensome to the drug maker and that they need the native files “in order to utilize sophisticated analytic tools,” but Pfizer asserts that native production can’t be redacted or reviewed without substantial time and expense.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
